LILLY Verve-102 single infusion cuts PCSK9 up to 88%, LDL-C up to 62% in Phase 1b; effect durable to 18 months; no serious treatment-related AEs; FDA Fast Track; Phase 2 Planned By Year-End

2026-05-25

LILLY Verve-102 single infusion cuts PCSK9 up to 88%, LDL-C up to 62% in Phase 1b; effect durable to 18 months; no serious treatment-related AEs; FDA Fast Track; Phase 2 Planned By Year-End